Sanofi, Glaxo to Supply 200 million Covid vaccine doses to Covax

By: |
Updated: Oct 28, 2020 1:28 PM

Sanofi and GlaxoSmithKline Plc said they’ve agreed to make available 200 million doses of the experimental Covid vaccine they’re jointly developing to Covax, a global effort to provide shots for developing nations.

The experts concurred that from the current less-than-a-dozen frontrunners in Phase 3 trials, or the final stage, the Novavax one is the more suitable vaccine for India.

Sanofi and GlaxoSmithKline Plc said they’ve agreed to make available 200 million doses of the experimental Covid vaccine they’re jointly developing to Covax, a global effort to provide shots for developing nations.

The drugmakers signed the supply arrangement with Gavi, the Vaccine Alliance, according to a statement. Gavi is among the groups working with the World Health Organization to ensure access to immunization for people around the world.

The U.S. and other wealthy nations have been buying up most of the shots expected to be developed and tested early. Sanofi’s shot, boosted by an adjuvant from Glaxo, is in early-stage human testing with results anticipated in December. The start of a final-stage trial is expected by the end of the year, according to the statement.

About 180 countries and regions, including China, have signed on to Covax to spread access to pandemic vaccines. The U.S. has not joined in the effort. The Serum Institute of India also has agreements to make experimental pandemic shots from AstraZeneca Plc, one of the fastest-moving Covid vaccine companies, and Novavax Inc. for eligible countries.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Why are all the prominent Covid-19 vaccines developed by women?
2Oxford-AstraZeneca Covid vaccine error: What is the way forward for Covishield in India
3Affordable, safe COVID-19 vaccination to be ready soon in India, says PM Modi